VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528

Predictive value of a serum-based proteomic test in non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors: a meta-analysis

“…Thirteen studies (three articles and 10 conference abstracts) were excluded from the meta-analysis 22-34 , leaving seven studies (six articles and one conference abstract) that fulfilled the eligibility criteria [15][16][17][18][19][20][21] . The reasons for not including these 12 studies in the meta-analysis were the following: no HR or CI, survival curve or p value reported [22][23][24][25][26][27] , or same cohort of patients reported in other studies [28][29][30][31][32][33][34] . Table 1 summarizes the clinical characteristic of patients enrolled in these included studies.…”

“…As shown, 11 cohorts collected from seven studies were suitable for final analysis and most of them dealt with the advanced (stage IIIB-IV) NSCLC patients. The number of patients in these included cohorts ranged from 29 20 to 139 15 with an average value of 64, and six cohorts' sizes were below the mean 16,17,[19][20][21] . Among all cohorts, nine received erlotinib-containing treatment while the other two received gefitinib single agent therapy 15 .…”

“…Then this classifier was commercialized and applied in multiple clinical trials. Many studies have found that this serum-based proteomic test could provide predictive information about clinical outcome in NSCLC patients following treatment with EGFR-TKIs [16][17][18][19][20][21] . In addition to these NSCLC studies, studies concerning other epithelial tumors also demonstrated the ability of the test to separate patients into two groups with better and worse outcomes.…”

“…This novel test uses the integrated intensities of eight mass spectral peaks and classifies patients into 'good' and 'poor' status. Multiple studies have shown that 'good' patients could benefit more from EGFR-TKI therapy than 'poor' ones [15][16][17][18][19][20][21] . Another study has also indicated that 'poor' patients have worse survival on EGFR-TKIs than on chemotherapy -chemotherapy should be the preferred option for them 22 .…”

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay

“…Early reports had shown that a proteomic signature in serum was significantly associated with survival outcome in patients with advanced NSCLC [2,14] and it was associated with benefit from erlotinib therapy. [5,7] In one study, mass spectra from patient sera were independently obtained at two institutions, were found to be highly concordant, and were used to generate an algorithm predictive of time to progression and OS. [3] This prediction algorithm was then validated in a blinded manner in two independent cohorts of NSCLC patients treated with EGFR TKIs.…”